Associated Papers
In Silico Binary Classification of Catalytic Function (Unaffected or Impaired) of Flavin-Containing Monooxygenase 3 (FMO3) Variants and in Vitro Validation Using New Variants Found in a Japanese Genome Resource Database.
Shimizu M et al.
Biological & Pharmaceutical Bulletin, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources.
Makiguchi M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Ligand stabilization and effect on unfolding by polymorphism in human flavin-containing monooxygenase 3.
Catucci G et al.
International Journal of Biological Macromolecules, 2020
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
Phillips IR et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Uncoupled human flavin-containing monooxygenase 3 releases superoxide radical in addition to hydrogen peroxide.
Catucci G et al.
Free Radical Biology & Medicine, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Nicotine-N'-Oxidation by Flavin Monooxygenase Enzymes.
Perez-Paramo YX et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2019
Association of FMO3 Variants with Blood Pressure in the Atherosclerosis Risk in Communities Study.
Bryant TS et al.
International Journal of Hypertension, 2019
Inactivation mechanism of N61S mutant of human FMO3 towards trimethylamine.
Gao C et al.
Scientific Reports, 2017
Human flavin-containing monooxygenase 3: Structural mapping of gene polymorphisms and insights into molecular basis of drug binding.
Gao C et al.
Gene, 2016
GESPA: classifying nsSNPs to predict disease association.
Khurana JK et al.
Bmc Bioinformatics, 2015
Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
Yamazaki H et al.
Biochemical Pharmacology, 2013
Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder.
Christodoulou J
Journal of Paediatrics and Child Health, 2012
Flavin-containing monooxygenases: mutations, disease and drug response.
Phillips IR et al.
Trends in Pharmacological Sciences, 2008
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Yeung CK et al.
Archives of Biochemistry and Biophysics, 2007
Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants.
Koukouritaki SB et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.
Koukouritaki SB et al.
Molecular Pharmacology, 2005
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Trimethylaminuria and a human FMO3 mutation database.
Hernandez D et al.
Human Mutation, 2003
Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria.
Zhang J et al.
Pharmacogenetics, 2003
Fish odour syndrome with features of both primary and secondary trimethylaminuria.
Fraser-Andrews EA et al.
Clinical and Experimental Dermatology, 2003
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities.
Park CS et al.
Pharmacogenetics, 2002
Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome.
Dolphin CT et al.
Pharmacogenetics, 2000
A novel mutation in the flavin-containing monooxygenase 3 gene (FMO3) of a Norwegian family causes trimethylaminuria.
Allerston CK et al.
Molecular Genetics and Metabolism, 0